PROGESTIN THERAPY FOR
ENDOMETRIAL CANCER
For young women with early-stage, low-grade endometrial cancer who wish to preserve fertility, progestin therapy offers a non-surgical route to remission before definitive treatment.
analyticsAt a Glance
- check_circleComplete remission rate up to 80% in grade 1, stage 1A endometrioid endometrial cancer
- check_circleUsed primarily as fertility-preserving therapy before definitive hysterectomy
- check_circleRequires 3-monthly hysteroscopy and biopsy to confirm response
- check_circleRelapse rate after stopping progestins is 25โ35% โ hysterectomy recommended after childbearing
Who Qualifies for Fertility-Sparing Progestin Therapy?
Progestin therapy is not appropriate for all endometrial cancers โ strict eligibility criteria must be met to ensure it is safe to defer surgery.
โProgestin therapy is not a permanent substitute for surgery โ it is a bridge to allow fertility before definitive treatment.โ
Required Criteria for Eligibility
Grade 1 (well-differentiated) endometrioid adenocarcinoma; stage 1A confirmed by MRI (no myometrial invasion >50%); no lymph node involvement; no extrauterine disease; strong desire to preserve fertility; able to comply with intensive monitoring.
Not Eligible
Grade 2 or 3 tumours, serous or clear cell histology, any myometrial invasion on MRI, elevated CA-125 suggesting extrauterine spread, or patients who do not intend to pursue pregnancy โ for these cases, hysterectomy is the standard recommendation.
The Progestin Therapy Protocol
Progestin therapy requires a structured protocol with regular monitoring โ response must be confirmed before any decision to attempt pregnancy or defer surgery.
- 1
Baseline Assessment
Complete MRI pelvis, hysteroscopy and D&C, endometrial biopsy, CA-125, genetic testing (Lynch syndrome screening), and fertility consultation.
- 2
Progestin Initiation
Medroxyprogesterone acetate (MPA) 500mg/day orally or megestrol acetate 160mg/day. LNG-IUS (Mirena) is an alternative for local delivery with fewer systemic side effects.
- 3
3-Monthly Hysteroscopy and Biopsy
Every 3 months: hysteroscopy with directed biopsy to confirm response. Imaging alone is insufficient โ histological confirmation of regression is required.
- 4
Response Assessment at 6 Months
If complete histological remission is confirmed at 6 months, patient may attempt conception (with fertility specialist co-management) or continue progestins for a further 6 months.
- 5
Definitive Surgery After Childbearing
Hysterectomy with bilateral salpingo-oophorectomy is strongly recommended after completing childbearing โ relapse risk without surgery is 25โ35% within 2 years.
Progestin Therapy Efficacy Data
- 76โ80%Complete response rate โ grade 1, stage 1AAcross multiple systematic reviews in well-selected patients treated with MPA or megestrol.
- 25โ35%Relapse rate within 2 years of stopping progestinsEmphasising that surgery after completed childbearing is essential โ progestins are not curative.
- 40โ50%Live birth rate in women attempting conception after remissionWith assisted reproduction (IVF) support, approximately 40โ50% of women achieve live birth after progestin-induced remission.
Progestin Options for Endometrial Cancer
Three main progestin approaches are used โ oral MPA, oral megestrol, and levonorgestrel IUD. Each has different delivery, side effect, and monitoring implications.
| Agent | Dose | Route | Advantages | Limitations |
|---|---|---|---|---|
| Medroxyprogesterone acetate (MPA) | 500mg/day | Oral | Most studied; cheap; widely available | Systemic side effects: weight gain, bloating, mood changes |
| Megestrol acetate | 160mg/day | Oral | Alternative to MPA with similar efficacy | Similar systemic side effects to MPA |
| Levonorgestrel IUD (LNG-IUS) | 52mg device | Intrauterine | Local delivery โ fewer systemic side effects; can remain in place during monitoring | Requires IUD insertion; may be displaced; monitoring hysteroscopy must remove and replace device |
Frequently Asked Questions
Progestin Therapy Practicalities
How long will I need to take progestins before knowing if they are working?
The first response assessment is at 3 months. Most complete responses occur by 6 months โ patients who show no response or progression at 6 months should proceed to hysterectomy without further delay. Continuing progestins beyond 6 months in non-responders is not recommended.
Are there risks to delaying surgery for progestin therapy?
Yes โ there is a small risk of disease progression (upstaging) during progestin therapy, particularly if selection criteria are not strictly applied. An MRI and biopsy at every 3-month assessment catches progression before it becomes unmanageable. Patients must understand that any sign of progression triggers immediate hysterectomy.
Can I access progestin therapy with monitoring in India or China through CancerFax?
Yes. Tata Memorial Hospital Mumbai and Apollo Hospitals both have gynaecologic oncology programmes experienced in fertility-sparing progestin therapy. Chinese centres including Fudan University and SYSUCC also run progestin protocols. CancerFax coordinates case review and monitoring programme setup.
Is Lynch syndrome testing important before starting progestins?
Yes โ Lynch syndrome (hereditary mismatch repair deficiency) is found in 2โ5% of endometrial cancers and carries implications for surveillance of other cancers (colorectal, ovarian). Lynch syndrome does not preclude progestin therapy but should be known before decisions about oophorectomy timing.
More from the Hormone Therapy Resource Library
Explore other hormone therapy guides โ from aromatase inhibitors to ADT and monitoring protocols.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Questions About Progestin Therapy for Endometrial Cancer?
CancerFax reviews your endometrial cancer case and connects you with gynaecologic oncologists in India and China who specialise in fertility-sparing hormone therapy for endometrial cancer.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.